Dianthus Therapeutics (NASDAQ:DNTH) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research note released on Thursday morning, Benzinga reports. The brokerage currently has a $40.00 target price on the stock.

DNTH has been the subject of several other research reports. Wedbush lowered their target price on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an outperform rating for the company in a report on Friday, August 9th. Robert W. Baird assumed coverage on Dianthus Therapeutics in a report on Friday, July 26th. They issued an outperform rating and a $58.00 price objective for the company. Lifesci Capital upgraded Dianthus Therapeutics to a strong-buy rating in a report on Tuesday, June 11th. Baird R W upgraded shares of Dianthus Therapeutics to a strong-buy rating in a report on Friday, July 26th. Finally, Cantor Fitzgerald initiated coverage on Dianthus Therapeutics in a research report on Thursday, June 27th. They issued an overweight rating for the company. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of Buy and an average target price of $44.71.

Dianthus Therapeutics Price Performance

DNTH opened at $27.24 on Thursday. The firm has a market cap of $799.47 million, a P/E ratio of -4.67 and a beta of 1.85. Dianthus Therapeutics has a 1-year low of $6.58 and a 1-year high of $33.77. The company has a 50 day simple moving average of $27.91 and a two-hundred day simple moving average of $26.20.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The company had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. Equities analysts anticipate that Dianthus Therapeutics will post -2.32 earnings per share for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several hedge funds have recently added to or reduced their stakes in DNTH. SG Americas Securities LLC purchased a new position in Dianthus Therapeutics in the 2nd quarter valued at $112,000. The Manufacturers Life Insurance Company purchased a new stake in Dianthus Therapeutics during the 2nd quarter worth about $236,000. WINTON GROUP Ltd acquired a new position in Dianthus Therapeutics in the 2nd quarter valued at about $265,000. Point72 DIFC Ltd purchased a new position in Dianthus Therapeutics in the 2nd quarter valued at about $334,000. Finally, Virtu Financial LLC purchased a new position in shares of Dianthus Therapeutics during the first quarter valued at approximately $390,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.